Foresight Diagnostics News and Activities

Headquarters: India

Foresight Diagnostics is owned by Quest Diagnostics.

Quest Diagnostics is one of the...

Quest Diagnostics is a company listed under the stock ticker DGX (US).

Quest Diagnostics has a direct presence in 4 countries.

Quest Diagnostics has 6 subsidiaries including Centogene, Foresight Diagnostics and Haystack Oncology.

They are in:

Acquisition, funding and merger involving Quest Diagnostics.

View the org chart displaying its 13 main executives

Mckenzie Carlisle who was Senior Director, Regulatory Operations & Compliance, becomes Senior Director, Regulatory Affairs & Quality Assurance (posted on March 10 2026).

Timothy Wentworth has joined the company as Director (posted on March 13 2026).
Benjamin Beauvalot has joined the company as Senior Vice President, Chief Strategy and Mergers and Acquisitions Officer (posted on February 26 2026).

Create your alert
to follow the executive moves at Foresight Diagnostics.

The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
Tissium has just announced a $60 Million fundraising (posted on July 8 2026).